16th Mar 2006 07:01
Sinclair Pharma PLC16 March 2006 Sinclair Wins 2006 Oral & Dental Care Product of the Year Award Godalming (UK) 16 March 2006: Frost & Sullivan the international managementconsultancy, has awarded its prestigious 2006 Oral and Dental Care Product ofthe Year Award to Sinclair Pharma plc for Decapinol(R), Sinclair's innovativeand outstanding product for oral plaque reduction and the treatment ofgingivitis. Frost and Sullivan analysts believe that Decapinol(R) Oral Rinse hasgiven a whole new dimension to complete oral hygiene. Decapinol(R) Rinse isregistered both in the US (prescription only) and in the EU where its lineextensions Decapinol(R) Toothpaste and Gel are also licensed and where Rinse hasalready been launched in Italy and Spain. The Frost & Sullivan Award for Product of the Year is presented each year to thecompany that has demonstrated excellence in new products and technologies withintheir industry. Sinclair Pharma plc has shown outstanding innovation bydeveloping and securing regulatory approval in various therapeutic areas withemerging products and technologies. (See Frost & Sullivan Award Criteriafollowing release). To choose a recipient of this Award, the Frost & Sullivan analyst team tracksall new product launches, R&D spending, products in development, and new productfeatures and modifications. This is accomplished through interviews with all themarket participants and extensive secondary and technology research. All newproduct launches and new products in development within each company arecompared and evaluated based on the degree of innovation and patient benefit. Frost & Sullivan believe that Decapinol(R) represents a revolutionaryachievement in new dental technology through a combination of its barriermechanism of action, clinically proven efficacy and the 'first of its kind'regulatory approval from the US FDA. Frost & Sullivan believe that Sinclair Pharma plc has tremendous potential inthe market with this breakthrough innovation, and that it will pave the way formore revolutionary products in the future. For its development and introductionof a novel new treatment to control gingivitis, Sinclair Pharma plc is thedeserving recipient of the 2006 Frost & Sullivan Oral & Dental Care Product ofthe Year Award. Commenting Dr Michael Flynn, Chief Executive Sinclair Pharma said: "We arenaturally delighted to have received this prestigious US award in one of our keyfocus areas, oral health, especially as this award is from the enormouslyimportant US market. The FDA also recently authorized Sinclair to include"Treatment of Plaque" in our US Decapinol(R) product labeling and given itsnovel approach to gingivitis, Sinclair believes that Decapinol(R) has thepotential to make a significant impact on the mouthwash and rinse market both inthe US and other markets" Sinclair Pharma plc, based in Godalming in the UK is quoted on the AlternativeInvestment Market (AIM) on the London Stock Exchange and focuses on theacquisition and development of niche patented pharmaceutical products in thefields of oral health and dermatology, and bringing them rapidly to theinternational market place. Enquiries: Sinclair Pharma plcUK ContactsDr Michael Flynn, CEO Tel: +44 (0) 1483 426 644John Barrington-Carver (Media Enquiries) Tel: +44 (0) 7831 655 630 Financial DynamicsBen Atwell / John Gilbert Tel +44 (0) 207 831 3113 US ContactMichael Killeen, Vice President Tel: +1 972 478 4380 Notes to Editors Sinclair Pharma plc: Sinclair Pharma plc based in Godalming in the UK, is quoted on the AlternativeInvestment Market (AIM) on the London Stock Exchange and has focused on theacquisition and development of niche patented pharmaceutical products in thefields of oral health, oncology support and dermatology, and bringing them tothe international market place via out-licensing partners. The Company combines product evaluation, product development, regulatory andbusiness development expertise to add value to its acquired and in-housedeveloped products. A key element of the Sinclair business model is to minimiserisk and exposure by avoiding involvement in lengthy R&D programmes and rapidlyachieving global distribution through a network of marketing partners. TheCompany has already licensed its products for distribution in over 50 countriesaround the world. About Frost & Sullivan: Frost & Sullivan, a global growth consulting company, has been partnering withclients to support the development of innovative strategies for more than 40years. The company's industry expertise integrates growth consulting, growthpartnership services, and corporate management training to identify and developopportunities. Frost & Sullivan serves an extensive clientele that includesGlobal 1000 companies, emerging companies, and the investment community byproviding comprehensive industry coverage that reflects a unique globalperspective and combines ongoing analysis of markets, technologies,econometrics, and demographics. For more information, visit www.frost.com. "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of1995: Some or all of the statements in this document that relate to futureplans, expectations, events, performances and the like are forward-lookingstatements, as defined in the US Private Securities Litigation Reform Act of1995. Actual results of events could differ materially from those described inthe forward- looking statements due to a variety of factors. FROST & SULLIVAN AWARD STATEMENT Award Description Research Methodology Measurement Criteria The Frost & Sullivan Award for To choose a recipient of this In addition to the methodology describedProduct of the Year is presented Award, the analyst team tracks all above, there are specific criteria usedeach year to the company that has new product launches, R&D spending, to determine final competitor rankingsdemonstrated excellence in new products in development, and new in this industry. The recipient of thisproducts and technologies within product features and modifications. Award has excelled based on one or moretheir industry. The recipient This is accomplished through of the following criteria:company has shown innovation by interviews with all the marketlaunching a broad line of emerging participants and extensive • Significance of new product(s) in theirproducts and technologies. secondary and technology research. industry All new product launches and new products in development in each • Competitive advantage of new product(s) company are compared and evaluated in their industry based on the degree of innovation and customer satisfaction. • Product innovation in terms Companies are then ranked by number of unique or revolutionary technology of new product launches and new products in development. • Product acceptance in the marketplace • New product value-added services provided to customers • Number of competitors with similar product(s) 2006 Oral & Dental Care Product of the Year Award Award Recipient: Sinclair Pharma plc Frost & Sullivan confers the 2006 Oral and Dental Care Product of the Year Awardon Sinclair Pharma plc for its innovative and outstanding product for oralplaque reduction and the treatment of gingivitis. The Decapinol(R) Oral Rinsefrom Sinclair Pharma plc has given a whole new dimension to complete oralHygiene. Sinclair Pharma plc: The Company Sinclair Pharma plc is an international pharmaceutical company headquartered inGodalming, Surrey (UK), with a primary focus on Oral health, Oncology supportand Dermatology. It was founded in 1971, and through acquisitions, hasestablished a recognized place in the market for gaining US FDA regulatoryapproval of innovative oral and dental care products in addition to similarregulatory approvals in the field of dermatology. Most notably, itsrevolutionary oral rinse, Decapinol(R), aids in gingivitis control where regulartooth brushing and flossing has not sufficed. DecapinolTM Oral Rinse: Addressing a Critical Need for Oral Plaque Reduction andGingivitis Control Gingivitis is most often caused by oral plaque, which contains bacteria andtheir toxins that affect the gingiva. Plaque-associated gingivitis is aninflammation of the gingival, particularly interdentally and around the gingivalmargins. Studies have shown that the key to preventing and controllingconditions like gingivitis and periodontal disease is having a good oralcleaning regimen that removes plaque that causes the disorder. Decapinol(R) is a need based innovation that aims at preventing oral plaque andbacteria from sticking to the tooth/gingival surface and also prevents theadhesion of bacteria to one another by using a revolutionary surfactanttechnology that acts as a physical barrier for bacterial /plaque adhesion. Frost & Sullivan is impressed by the unique advantage that Decapinol(R) Oral Rinse offers in aiding oral plaque reduction and gingivitis control. This newtechnology could well pave the way for total oral hygiene solutions in the nearfuture. Revolutionary Technology: Mechanism of Action A key surface-acting agent in the product prevents oral bacteria from adheringand colonizing onto tooth surfaces, which in turn inhibits the formation ofdental plaque. The novel mechanism of action is an excellent complement forregular tooth brushing and flossing. This reduction in oral plaque curtails theharmful bacterial toxins from attacking the tooth or gingiva. Decapinol(R) wasapproved by the FDA in April of 2005 and is registered as a prescription MedicalDevice in the U.S. and some European countries. The Decapinol(R) Oral Rinse is registered as a medical device and not as a drugbecause of its novel mode of action, which creates a physical, rather thanchemical barrier. This also helps in the maintenance of the ecological balanceof the oral microbial flora, essential for maintaining healthy teeth andgingiva. The action of Decapinol(R) is unique from other available therapeuticagents in that the mechanism of action is more of a surface acting nature ratherthan the broad spectrum antibacterial action of traditional rinses. The interference with the bioadherent properties of oral plaque/bacteria makesthe mechanical debridement of plaque an easy job with conventional toothbrushing and flossing. In addition to helping break up existing plaque,Decapinol also helps to prevent the formation of new plaque. This product is ofvital importance to the patient population who need an efficient oral hygieneregime to prevent the progression of gingivitis to periodontitis. Benefits of Decapinol(R) Offer Clear Advantages over Alternatives Clinical studies have reported that DecapinolTM decreases gingivitis up to 57%when used as instructed with recommended brushing and flossing, demonstratingthe efficacy of this revolutionary new product. Additionally, it is convenientand easy to use at home, it can be incorporated into a patient's normal oralhygiene routine and does not promote the staining or the coloring of the toothsurface, as may occur with other antibacterial mouth rinses. Lastly, asDecapinol(R) is not based on an antibacterial agent, it does not adverselyaffect the ecological balance of oral flora in the oral cavity. These benefits are highly significant in the control of gingivitis andperiodontitis progression, a disease condition which affects the periodontalligament and alveolar sockets. This latest technology breakthrough significantly increases the ability ofclinicians to intelligently control gingivitis progression and removes asignificant stumbling block in patient compliance with an effective oral hygieneroutine. Frost & Sullivan believes that Sinclair Pharma plc has tremendous potential inthe market with this breakthrough innovation, and that it will pave the way formore revolutionary products in the future. For its development and introductionof a novel new treatment to control gingivitis, Sinclair Pharma plc is thedeserving recipient of the 2006 Frost & Sullivan Oral & Dental Care Product ofthe Year Award. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Sinclair Pharma